Clinical awareness and diagnosis of male hypogonadism

Journal of Men's Health

Volumn 5, Issue SUPPL., 2008, Pages

  Jones, T Hugh ^a  

^a Barnsley Hospital Foundation NHS Trust   (United Kingdom)

Author keywords

Cardiovascular disease; Diabetes mellitus; Metabolic syndrome; Testosterone

Indexed keywords

AMLODIPINE; ATORVASTATIN; HEMOGLOBIN A1C; INSULIN; LEPTIN; NIFEDIPINE; PHOSPHODIESTERASE V INHIBITOR; SEX HORMONE BINDING GLOBULIN; SILDENAFIL; SIMVASTATIN; TESTOSTERONE;

ACUTE DRUG ADMINISTRATION; ANDROGEN DEFICIENCY; ANGINA PECTORIS; ARTICLE; ATHEROSCLEROSIS; AWARENESS; BIOAVAILABILITY; BIOCHEMISTRY; BONE; BRAIN; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CAUSE OF DEATH; CIRCADIAN RHYTHM; DIAGNOSTIC ERROR; DIET THERAPY; DRUG BINDING; DRUG EFFECT; DRUG MECHANISM; DRUG TREATMENT FAILURE; ERECTILE DYSFUNCTION; FATIGUE; FRACTURE; GLYCEMIC CONTROL; HEART FAILURE; HEART INDEX; HEMOGLOBIN BLOOD LEVEL; HORMONE BLOOD LEVEL; HYPOGONADISM; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; KINESIOTHERAPY; LIBIDO DISORDER; METABOLIC SYNDROME X; METABOLISM; MOOD DISORDER; MUSCLE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PHYSICIAN; PHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; RISK FACTOR; SCREENING TEST; ST SEGMENT DEPRESSION; SYMPTOMATOLOGY; TESTOSTERONE BLOOD LEVEL;

EID: 50249107423     PISSN: 18756867     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jomh.2008.03.014     Document Type: Article

References (68)

1. Nieshlag E., Behre H.M., Bouchard P., Corrales J., Jones T.H., Stalla G., et al. Testosterone replacement therapy: current trends and future directions. Hum Reprod Update 10 (2004) 409-419
2. Nieschlag E., Swerdloff R., Behre H.M., Gooren L.J., Kaufman J.M., Legos J.J., et al. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM and EAU recommendations. J Androl 27 (2006) 135-137
3. Kapoor D., Goodwin E., Channer K.S., and Jones T.H. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolemia in hypogonadal men with Type 2 diabetes. Eur J Endocrinol 154 (2006) 899-906
4. Malkin C.J., Pugh P.J., Kapoor D., Jones R.D., Channer K.S., Jones T.H., et al. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab 89 (2004) 3313-3318
5. Webb C.M., McNeill J.G., Hayward C.S., deZeigler D., and Collins P. Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease. Circulation 100 (1999) 1690-1696
6. English K.M., Steeds R.P., Diver M.J., Jones T.H., and Channer K.S. Low dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina. Circulation 102 (2000) 1906-1911
7. Malkin C.J., Pugh P.J., West J.N., van Beek E.J., Jones T.H., Channer K.S., et al. Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. Eur Heart J 27 (2006) 54-56
8. Jones T.H. Testosterone associations with erectile dysfunction diabetes and the metabolic syndrome. Eur Urol (suppl) 6 (2007) 847-857
9. Moffat S.D., Zonderman A.B., Metter E.J., Kawas C., Blackman M.R., Harman S.M., et al. Free testosterone and risk for Alzheimer's disease in older men. Neurology 62 (2004) 188-193
10. Shores M.M., Matsumoto A.M., Sloan K.L., and Kivlahan D.R. Low serum testosterone and mortality in male veterans. Arch Intern Med 166 (2006) 1660-1665
11. Laughlin G.A., Barrett-Connor E., and Bergstrom J. Low testosterone and mortality in older men. J Clin Endocrinol Metab (2007) epub ahead of print
12. Araujo A.B., Kupelian V., Page S.T., Handelsman D.J., Bremner W.J., and McKinlay J.B. Sex steroids and all-cause mortality and cause-specific mortality in men. Arch Int Med 167 (2007) 1252-1260
13. Bhasin S., Cunningham G.R., Hayes F.J., Matsumoto A., Snyder P.J., Swerdloff R.S., et al. Testosterone therapy in adult men with androgen deficiency syndromes: An Endocrine Society Clinical Practise Guideline. J Clin Endocrinol Metab 91 (2006) 1995-2010
14. Morley J.E., Charlton E., Patrick P., Kaiser F.E., Cadeau P., McCready D., et al. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism 49 (2000) 1239-1242
15. Heinemann L.A.J., Zimmermann T., Vermeulen A., and Thiel C. A new aging males' symptoms rating scale. Aging Male 2 (1999) 105-114
16. Rosner W., Auchus R.J., Azziz R., Sluss P.M., and Raff H. position statement: utility,limitations, and pitfalls in measuring testosterone: An Endocrine Society position statement. J Clin Endocrinol Metab 92 (2007) 405-413
17. Vermeulen A., Verdonck L., and Kaufman J.M. A critical evaluation of simple methods for estimation of free testosterone in serum. J Clin End Metab 84 (1999) 3666-3672
18. de Ronde W., van der Schouw Y.T., Pols H.A., Gooren L.J., Muller M., Grobbee D.E., et al. Calculation of bioavailable and free testosterone in men: a comparison of 5 published algorithms. Clinical Chemistry 52 (2006) 1777-1784
19. Morris P.D., Malkin C.J., Channer K.S., and Jones T.H. A mathematical comparison of techniques to predict biologically active testosterone in a cohort of 1072 men. Eur J Endocrinol 151 (2004) 241-249
20. Bhasin S., Woodhouse L., Casaburi R., Singh A.B., Bhasin D., Berman N., et al. Testosterone dose-resonse relationships in healthy young men. Am J Physiol Endocrinol Metab 281 (2001) E1172-E1181
21. Snyder P.J., Peachey H., Hannoush P., Berlin J.A., Loh L., Holmes J.H., et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 84 (1999) 1966-1972
22. Stellato R.K., Feldman H.A., Hamdy O., Horton E.S., McKinlay J.B., et al. Testosterone, sex hormone binding globulin and the development of Type 2 diabetes in middle aged men: prospective results form the Massachusetts Male Aging Study. Diabetes Care 23 4 (2000) 490-494
23. Haffner S.M., Shaten J., Stern M.P., and Katz M.S. Low levels of sex hormone binding globulin and testosterone predict the development of non insulin dependent diabetes mellitus in men. Am J Epidemiol 143 (1996) 889-897
24. Oh J.Y., Barrett-Connor E., Wedick N.M., and Wingard D.L. Endogenous sex hormones and the development of type 2 diabetes in older men and women:the Rancho Bernardo Study. Diabetes Care 25 1 (2002) 55-60
25. Laaksonen D.E., Niskanen L., Punnonen K., Nyyssonen K., Tuomainen T.P., Valkonen V.P., et al. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 27 (2004) 1036-1041
26. Kupelian V., Page S.T., Araujo A.B., Travison T.G., Bremner W.J., McKinlay J.B., et al. Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with the development of the metabolic syndrome in non-obese men. J Clin Endocrinol Metab 91 (2006) 843-850
27. Blouin K., Després J.P., Couillard C., Tremblay A., Prud'homme D., Bouchard C., et al. Contribution of age and declining androgen levels to features of the metabolic syndrome in men. Metabolism 54 (2005) 1034-1040
28. Kapoor D., Malkin C.J., Channer K.S., and Jones T.H. Androgens, insulin resistance and vascular disease in men. Clin Endocrinol (Oxf) 63 (2005) 239-250
29. Kapoor D., Aldred H., Clarke S., Channer K.S., and Jones T.H. Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes. Correlations with bioavailable testosterone and visceral adiposity. Diabetes Care 30 (2007) 911-917
30. Selvin E., Feinleib M., Zhang L., Rohrmann S., Rifai N., Nelson W.G., et al. Androgens and diabetes in men. Results from the third national health and nutrition examination survey. Diabetes Care 30 (2007) 234-238
31. Zitzmann M., Faber S., and Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. JCEM 91 (2006) 4335-4337
32. Muller M., Grobbee D.E., den Tonkelaar I., Lamberts S.W., and van der Schouw Y.T. Endogenous sex hormones and metabolic syndrome in aging men. J Clin Endocrinol Metab 90 (2005) 2618-2623
33. Corona G., Mannucci E., Schulman C., Petrone L., Mansani R., Cilotti A., et al. Psychobiologic correlates of the metabolic syndrome and associated sexual dysfunction. Eur Urol 50 (2006) 595-604
34. Keating N.L., O'Malley J., and Smith M.R. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24 (2006) 4448-4456
35. Yassin E., Saad F., Guillaume A., and Heinemann K. Effect of androgen deprivation on glycaemic control and on biochemical cardiovascular risk factors in men with diabetes. J Urol 175 suppl (2006) 385
36. Svartberg J., von Mühlen D., Mathiesen E., Joakimsen O., Bønaa K.H., Stensland-Bugge E., et al. Low testosterone levels are associated with carotid atherosclerosis in men. J Intern Med 259 6 (2006) 576-582
37. Heufelder A, Gooren L, Saad F et al., Testosterone replacement enhances the favourable effects of exercise and dietary modificationin hypogonadal men with type 2 diabetes. The Endocrine Society's 89th annual meeting program & Absracts 2007;OR-55-5:151.
38. Stratton I.M., Adler A.I., Neil H.A., Matthews D.R., Manley S.E., Cull C.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS35): prospective observational study. BMJ 321 (2000) 405-412
39. Cohen P.G. The hypogonadal-obesity cycle. Med Hypotheses 52 (1999) 49-51
40. Isidori A.M., Caprio M., and Strollo F. Leptin and androgens in male obesity: evidence for leptin contribution to reduced androgen levels. J Clin Endocrinol Metab 84 (1999) 3673-3680
41. Stanworth R.D., Kapoor D., Channer K.S., and Jones T.H. Testosterone levels correlate positively with HDL cholesterol levels in men with type 2 diabetes. Endocrine Abstracts 14 (2007) P628
42. Isidori A.M., Giannetta E., Gianfrilli D., Greco E.A., Bonifacio V., Aversa A., et al. Effect of testosterone on sexual function in men: results of meta-analysis. Clin Endocrinol (Oxf) 63 (2005) 239-243
43. Kratzik C.W., Schatzl G., Lunglmayr G., Rücklinger E., and Huber J. The impact of age, body mass index and testosterone on erectile dysfunction. J Urol 174 (2005) 240-243
44. Kapoor D., Clarke S., Channer K.S., and Jones T.H. Erectile dysfunction is associated with low testosterone levels and visceral adiposity in men with type 2 diabetes Int. J. Androl. 30 (2007) 500-507
45. Esposito K., Giugliano F., Martedì E., Feola G., Marfella R., D'Armiento M., et al. High proportions of erectile dysfunction in men with the metabolic syndrome. Diabetes Care 28 (2005) 1201-1203
46. Gazzaruso C., Giordanetti S., De Amici E., Bertone G., Falcone C., Geroldi D., et al. Relationship between erectile dysfunction and silent myocardial ischaemia in apparently uncomplicated type 2 diabetic patients. Circulation 110 (2004) 22-26
47. Kalinchenko S.Y., Kozlov G.I., Gontcharov N.P., and Katsiya G.V. Oral testosterone undecanoate reverses erectile dysfunction associated with diabetes mellitus in patients failing on sildenafil citrate therapy alone. Aging Male 6 (2003) 94-99
48. Aversa A., Isidori A.M., Spera G., Lenzi A., and Fabbri A. Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction. Clin Endocrinol (Oxf) 58 (2003) 632-638
49. Shabsigh R., Kaufman J., Steidle J., and Padma-Nathan H. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol 172 (2004) 658-663
50. Greenstein A., Mabjeesh N.J., Sofer M., Kaver I., Matzkin H., Chen J., et al. Does sildenafil combined with testosterone gel improve erectile dysfunction in hypogonadal men in whom testosterone therapy alone failed. J Urol 173 (2003) 530-532
51. Wespes E., Amar E., Hatzichristou D., Hatzimouratidis K., Montorsi F., Pryor J., Vardi Y., et al. EAU Guidelines on erectile dysfunction: An update. Eur Urol 49 (2006) 806-815
52. Jones R.D., Nettleship J.E., Jones T.H., and Channer K.S. Testosterone and atherosclerosis in aging men: Purported association and clinical implications. Am J Cardiovasc Drugs 5 (2005) 141-154
53. English K.M., Mandour O., Steeds R.P., Diver M.J., Jones T.H., Channer K.S., et al. Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms. Eur Heart J 21 (2000) 890-894
54. Fukui M., Kitagawa Y., Nakamura N., Kadono M., Mogami S., Hirata C., et al. Association between serum testosterone concentration and carotid atherosclerosis in men with Type 2 diabetes. Diabetes Care 26 (2003) 1869-1873
55. van den Beld A.W., Bots M.L., Janssen J.A., Pols H.A., Lamberts S.W., Grobbee D.E., et al. Endogenous hormones and carotid atherosclerosis in elderly men. Am J Epidemiol 157 (2003) 25-31
56. Svartberg J., von Mühlen D., Mathiesen E., Joakimsen O., Bønaa K.H., Stensland-Bugge E., et al. Low testosterone levels are associated with carotid atherosclerosis in men. J Intern Med 259 (2006) 576-582
57. De Pergola G., Pannacciulli N., Ciccone M., Tartagni M., Rizzon P., Giorgino R., et al. Free testosterone plasma levels are negatively associated with the intima-media thickness of the common carotid artery in overweight and obese glucose-tolerant young adult men. Int J Obes Relat Metab Disord 27 (2003) 803-807
58. Hak A.E., Witteman J.C., de Jong F.H., Geerlings M.I., Hofman A., Pols H.A., et al. Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam Study. J Clin Endocrinol Metab 87 (2002) 3632-3639
59. Muller M., van den Beld A.W., Bots M.L., Grobbee D.E., Lamberts S.W., van der Schouw Y.T., et al. Endogenous sex hormones and progression of carotid atherosclerosis in elderly men. Circulation 109 (2004) 2074-2079
60. Alexandersen P., Haarbo J., Byrjalsen I., Lawaetz H., and Christiansen C. Natural androgens inhibit male atherosclerosis. Circ Res 84 (1999) 813-819
61. Bruck B., Brehme U., Gugel N., Hanke S., Finking G., Lutz C., et al. Gender-specific differences in the effects of testosterone and estrogen on the development of atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol 17 (1997) 2192-2199
62. Larsen B.A., Nordestgaard B.G., Stender S., and Kjeldsen K. Effect of testosterone on atherogenesis incholesterol-fed rabbits with similar plasma cholesterol levels. Atherosclerosis 99 (1993) 79-86
63. Nettleship JE, Jones TH, Channer KS, Jones RD, Testosterone replacement therapy attenuates fatty streak formation and improves high-density lipoprotein cholesterol in the Tfm mouse: an effect independent of the classical androgen receptor. Circulation In press.
64. Jones R.D., Pugh P.J., Jones T.H., and Channer K.S. The vasodilatory action of testosterone: a potassium-channel opening or a calcium antagonistic action. Br J Pharmacol 138 (2003) 733-744
65. Scragg J.L., Jones R.D., Channer K.S., Jones T.H., and Peers C. Testosterone is a potent inhibitor of L-type Ca2+ channels. Biochim Biophys Res Comm 318 (2004) 503-506
66. Hall J., Jones R.D., Jones T.H., Channer K.S., and Peers C. Selective inhibition of L-type Ca2+ channels in A7r5 cells by physiological levels of testosterone. Endocrinology 147 (2006) 2675-2680
67. Pugh P.J., Jones R.D., West J.N., Jones T.H., and Channer K.S. Testosterone improves functional capacity and symptoms in men with heart failure. Heart 90 (2004) 446-447
68. Pugh P.J., Jones T.H., and Channer K.S. Acute haemodynamic effects of testosterone in men with chronic heart failure. Eur Heart J 24 (2003) 909-915